The medical community is buzzing about the new drug, a dual-action treatment showing significant results in preliminary studies . This innovative compound, a incretin receptor agonist alongside a glucose-dependent insulinotropic agent , appears to substantially decrease body mass and improve metabolic markers. Clinicians are indicating that it m… Read More